Fulcrum Asset Management LLP grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 3,648.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,622 shares of the company’s stock after purchasing an additional 5,472 shares during the quarter. Fulcrum Asset Management LLP’s holdings in TransMedics Group were worth $473,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Silvant Capital Management LLC purchased a new stake in TransMedics Group in the second quarter worth about $26,000. State of Wyoming purchased a new position in shares of TransMedics Group in the second quarter worth $31,000. Ancora Advisors LLC bought a new position in shares of TransMedics Group during the 2nd quarter valued at about $33,000. Persistent Asset Partners Ltd bought a new position in TransMedics Group during the second quarter valued at approximately $55,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of TransMedics Group by 700.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 800 shares of the company’s stock valued at $67,000 after acquiring an additional 700 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
TransMedics Group Price Performance
NASDAQ TMDX opened at $91.38 on Monday. The stock’s fifty day moving average price is $80.28 and its 200 day moving average price is $92.05. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.53 and a quick ratio of 4.15. The company has a market cap of $3.17 billion, a price-to-earnings ratio of 24.76, a PEG ratio of 1.62 and a beta of 2.14. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.21. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The firm had revenue of $203.01 million during the quarter, compared to analysts’ expectations of $178.06 million. During the same period last year, the business posted $0.66 earnings per share. The company’s revenue for the quarter was up 41.1% compared to the same quarter last year. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1.66 earnings per share for the current year.
Insider Buying and Selling at TransMedics Group
In related news, Director David Weill acquired 1,336 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the acquisition, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. This represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.
Analyst Ratings Changes
TMDX has been the topic of a number of recent research reports. UBS Group upped their price objective on TransMedics Group from $77.00 to $88.00 and gave the company a “neutral” rating in a research report on Monday, November 9th. TD Cowen reiterated a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a report on Tuesday, September 8th. Canaccord Genuity Group lifted their target price on TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, Wall Street Zen upgraded TransMedics Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $113.30.
Check Out Our Latest Stock Analysis on TMDX
TransMedics Group Company Profile
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
Further Reading
- Five stocks we like better than TransMedics Group
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
